Clinicopathological and Prognostic Significance of PRAME Overexpression in Human Cancer: A Meta-Analysis

Table 2

Subgroup analysis of the studies reporting the association of overexpression of PRAME and OS of cancer patients.

Stratified analysis	No. of studies	No. of patients	Pooled HRs (95% CI)		value	Heterogeneity
			Fixed	Random		(%)	value
Study location
Asia	7	1262	1.58 (1.36, 1.84)	1.41 (1.02, 1.95)	<0.001	51.3	0.06
Non-Asia	5	716	2.36 (1.81, 3.08)	2.36 (1.81, 3.08)	<0.001	0	0.78
Sample size
≥ 100	6	1298	1.65 (1.42, 1.92)	1.49 (1.04, 2.15)	<0.001	66.8	0.01
<100	6	680	2.14 (1.60, 2.85)	2.14 (1.60, 2.85)	<0.001	0	0.69
Index
qRT-PCR	6	908	1.79 (1.42, 2.26)	1.69 (1.02, 2.81)	0.043	75	0.01
IHC	4	430	1.78 (1.19, 2.69)	1.78 (1.19, 2.69)	0.005	0	0.96
Microarray	2	640	1.72 (1.44, 2.05)	1.72 (1.44, 2.05)	<0.001	0	0.69